To ensure confidentiality, the treatment allocation will be concealed from study personnel, outcome assessors, and participants. This will be achieved through the use of sequentially numbered sealed opaque envelopes. On the day of the surgery, the perfusionist will receive a sealed envelope with instructions on the cardioplegic solution to prepare and administer according to its specificities before administering anesthesia. To avoid any biases, the surgical team, patients, anesthetists, nurses, and laboratory staff will be blinded to the type of intervention used. After the surgery, the patients will be transferred to the ICU and monitored by a team with post-operative expertise in the specialty, according to standard institutional protocols. The team will also be blinded to the type of cardioplegia used during the surgery. The patients will then be transferred to the postoperative cardiology unit, where they will be managed until hospital discharge by the responsible team, following standard protocols, and also blinded to the type of intervention. The lead investigator, who will identify the outcomes and perform the statistical analyses, will also remain blind to the allocation of patients regarding the type of intervention. During the adjudication process, all researchers will be kept unaware of the patient's allocation to different interventions. The data obtained from the adjudication will be utilized in the final analysis of safety and effectiveness. All data will be evaluated by two authors independently, with quality control on data entry to verify amplitude and consistency.